Study of Circulating Cancer Cells in Patients With Metastatic Breast, Ovarian, Colon, or Pancreatic Cancer
RATIONALE: Counting the number of circulating cancer cells in samples of blood from patients with metastatic cancer may help doctors find out how much the cancer has spread.
PURPOSE: This research study is looking at the number of circulating cancer cells in patients with metastatic breast cancer, ovarian cancer, colon cancer, or pancreatic cancer.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Molecular Detection of Circulating Cancer Cells in Breast, Ovarian, Colon and Pancreatic Cancer|
- Frequency of circulating cancer cells (CTC) [ Time Frame: 1 day ] [ Designated as safety issue: No ]
- Variability in number of CTCs between patients with the same tumor type [ Time Frame: 1 day ] [ Designated as safety issue: No ]
- Correlation of the number of CTCs with extent of tumor burden as measured by tumor markers, imaging, and the number of metastatic sites and proliferation and apoptotic markers [ Time Frame: 1 day ] [ Designated as safety issue: No ]
|Study Start Date:||November 2007|
|Study Completion Date:||April 2010|
|Primary Completion Date:||April 2010 (Final data collection date for primary outcome measure)|
|Metastatic Breast Cancer|
|Metastatic Ovarian Cancer|
|Metastatic Pancreatic Cancer|
|Metastatic Colon Cancer|
|Stage 3 Ovarian Cancer|
|Locally Advanced Pancreatic Cancer|
- To assess frequency of circulating tumor cells (CTCs) in patients with metastatic ovarian, breast, pancreatic, and colon cancers.
- To assess the variability in number of CTCs between patients with the same tumor type.
- To correlate the number of CTCs with extent of tumor burden as measured by tumor markers, imaging, and the number of metastatic sites and proliferation and apoptotic markers.
OUTLINE: Blood samples are collected before treatment and analyzed using molecular detection techniques to detect circulating cancer cells. Samples are assessed by immunofluorescence for markers of proliferation and survival (e.g., EGFR, phosphorylated EGFR, AKT, phosphorylated AKT, cytokeratins, MAPK, Src, and FAK).
Please refer to this study by its ClinicalTrials.gov identifier: NCT00898781
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Principal Investigator:||Charles Erlichman, MD||Mayo Clinic|